Navigation Links
Eisai Inc. Announces Non-Exclusive Licensing Agreement with Generic Drug Manufacturer to Provide Generic Version of donepezil HCl 23 mg
Date:8/29/2013

WOODCLIFF LAKE, N.J., Aug. 29, 2013 /PRNewswire/ -- Eisai Inc. announced that the company has recently entered into a non-exclusive licensing agreement in the United States with a manufacturer of generic pharmaceuticals that grants certain rights, including the right to market and offer for sale a generic version of donepezil hydrochloride 23 mg and a non-exclusive license to Eisai Intellectual Property covering donepezil hydrochloride 23 mg, including U.S. Patent No. 8,481,565. This agreement applies to the United States only.

(Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO)

About Eisai Inc.
At Eisai Inc., human health care is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., our passionate commitment to patient care is the driving force behind our efforts to help address unmet medical needs. We are a fully integrated pharmaceutical business with discovery, clinical, manufacturing and marketing capabilities. Our key areas of commercial focus include oncology and specialty care (Alzheimer's disease, epilepsy and metabolic disorders). To learn more about Eisai Inc., please visit us at www.eisai.com/US

Eisai Inc. has affiliates that are part of a global product creation organization that includes R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania, as well as a global demand chain organization that includes manufacturing facilities in Maryland and North Carolina. Eisai'
'/>"/>

SOURCE Eisai Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Eisai Launches New Website Providing Employers with Educational Resource for Obesity Management
2. FDA Grants Orphan Drug Status To Eisais Investigational Compound (E7777) For Cutaneous T-Cell Lymphoma
3. For Treating Psoriatic Arthritis, Clinical Data and Thought Leaders Opinions Indicate that AbbVie/Eisais Humira Has the Best Clinical Profile Among Key Marketed Therapies
4. Eisai USA Foundation to Donate $1 Million to the Conquer Cancer Foundation of the American Society of Clinical Oncology
5. Eisai To Sponsor 7th Annual National Walk For Epilepsy To Help Raise Epilepsy Awareness
6. Lynn Kramer, MD, Appointed Chief Clinical Officer of Eisai Product Creation Systems
7. FDA Grants Orphan Drug Status To Eisais Lenvatinib
8. Eisai Oncology to Present New Research on Eribulin at 35th Annual San Antonio Breast Cancer Symposium
9. Eisai USA Foundation to Donate $100,000 to the Hurricane Sandy New Jersey Relief Fund, $50,000 to the American Red Cross
10. Epilepsia Publishes Results From Two Studies Of Eisais Perampanel
11. Shaji Procida Appointed Vice President and Chief Financial Officer of Eisai Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 2014  IRIDEX Corporation (NASDAQ: IRIX ) ... 2014 financial results after the market closes on ... release, the Company will host a conference call with ... on Thursday, July 31, 2014 to ... developments. Interested parties may access the live ...
(Date:7/24/2014)... 2014  IGI Laboratories, Inc. (NYSE MKT: IG), a New ... its financial results for the second quarter ended June 30, ... Total revenues of $6.5 million in the second quarter of ... 2013 , Total revenues of $13.3 million for the ... over the same period in 2013 , Total revenues ...
(Date:7/24/2014)... 2014 LSI Medience Corporation today announced ... Kineticos, a Raleigh-Durham, NC ... LSI Medience in identifying opportunities for Presepsin, a ... in clinical trials. The Presepsin biomarker ... of sepsis, prognosis of septic patients, early risk ...
Breaking Medicine Technology:IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7LSI Medience Corporation and Kineticos Sign Agreement Related to the Presepsin Biomarker in Sepsis Management and Treatment 2
... WATERTOWN, Mass.--(BUSINESS WIRE)--May 29, 2007 - Panacos,Pharmaceuticals, ... the next generation of antiviral,therapeutic products, today ... that HIV resistant to Protease Inhibitors (PI) ... resistance to the HIV,maturation inhibitor bevirimat in ...
... Taxotere(R) and on three investigational,agents (VEGF Trap, S-1 ... ASCO meeting, BRIDGEWATER, N.J., May 29, 2007 /PRNewswire-FirstCall/ ... abstracts,indicative of its oncology commitment have been accepted ... of Clinical Oncology,(ASCO) in Chicago, Illinois (June 1-5, ...
Cached Medicine Technology:Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have,Reduced Potential to Develop Resistance to Panacos' Bevirimat 2Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have,Reduced Potential to Develop Resistance to Panacos' Bevirimat 3Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 2Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 3Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 4Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 5Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 6Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 7Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 8Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 9Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 10Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 11Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 12
(Date:7/24/2014)... rats bearing human breast tumors, exposure to dim light ... cancer drug tamoxifen, according to data published in ... for Cancer Research. The negative effects of dim light ... a melatonin supplement during the night. , "Resistance to ... receptor-positive breast cancer," said Steven M. Hill, PhD, professor ...
(Date:7/24/2014)... Ticket Down is a reliable source for cheap Manchester ... Authority Field on July 26th. For the past four years, the ... the best club teams from around the world to North America ... weeks after its completion, fans – new and old alike – ... in the world compete. Some of these players were already members ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 The ... http://www.injurybeacon.com/granuflo-dialysis/lawsuit/ ) in the U.S. District Court, ... order for plaintiff medical information covered by the ... to the July 16th Order, U.S. District Judge ... for Fresenius Medical Care the right to receive ...
(Date:7/24/2014)... Association Executives (ASAE) announced its 2014 Power of A ... Society of Anesthesiologists (ASA). , The ASA Global ... Gold Award, one of the top honors from ASAE. ... the world through education on the global anesthesia crisis ... , ASA was also honored with a Power of ...
(Date:7/24/2014)... July 24, 2014 Pools and beaches are ... water can be dangerous, especially for small children, so ... safety. , According to the Centers for Disease Control and ... most at risk for water-related injuries and deaths. It’s important ... around water, so Amica is offering the following tips from ...
Breaking Medicine News(10 mins):Health News:Exposure to dim light at night may make breast cancers resistant to tamoxifen 2Health News:Manchester United vs. AS Roma Tickets Denver Sports Authority Field at Mile High: Ticket Down Cuts Ticket Prices for Guinness International Champions Cup Match 2Health News:Manchester United vs. AS Roma Tickets Denver Sports Authority Field at Mile High: Ticket Down Cuts Ticket Prices for Guinness International Champions Cup Match 3Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 2Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 3Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 4Health News:Keep Kids Safe in the Water with 5 Tips from Amica 2
... book, written by Dr. Vardit Rispler-Chaim of the Department ... Haifa, analyzes attitudes to people with various ... Middle Ages and the modern era. , In the ... and often within broad topics such as religious duties, ...
... focus on issues most critical to health care ... selected as new survey vendor, WASHINGTON, Dec. 12 ... non-profit organization of employer-based,health coalitions, released its 2008 eValue8(TM) ... health care purchasers to compare,the quality and efficiency of ...
... Dec. 12 INVEGA(TM) (paliperidone),Extended-Release Tablets showed ... open-label extension (OLE) study, according to a ... improved or,were stable, on average, over this ... to evaluate the long-term safety of INVEGA, ...
... had harder time fighting gum disease , , WEDNESDAY, ... harder to fight infections, and a weakened immune response ... Boston University researchers. , In experiments with mice infected ... had less ability to battle gum infection than their ...
... and Providers, AUSTIN, Texas, Dec. 12 ... report, U.S. taxpayers are annually defrauded of,about $60 ... health,care providers. A new system developed by S3 ... significant impact on reducing Medicare,and Medicaid fraud with ...
... by the,positive results of the 2007 Monitoring the Future ... in the right direction,with significant declines in overall teen ... for all measured age groups marking steady long-term,reductions in ... MTF, now in its 33rd year, is an ...
Cached Medicine News:Health News:National Business Coalition on Health Releases 2008 eValue8(TM) RFI 2Health News:National Business Coalition on Health Releases 2008 eValue8(TM) RFI 3Health News:INVEGA(TM) Shows Favorable Long-Term Safety Profile in a One-Year Study of Patients With Schizophrenia 2Health News:INVEGA(TM) Shows Favorable Long-Term Safety Profile in a One-Year Study of Patients With Schizophrenia 3Health News:INVEGA(TM) Shows Favorable Long-Term Safety Profile in a One-Year Study of Patients With Schizophrenia 4Health News:INVEGA(TM) Shows Favorable Long-Term Safety Profile in a One-Year Study of Patients With Schizophrenia 5Health News:INVEGA(TM) Shows Favorable Long-Term Safety Profile in a One-Year Study of Patients With Schizophrenia 6Health News:Obesity Weakens Immune Response 2Health News:Technology can Dramatically Reduce Billions of Dollars in Medicaid, Medicare Fraud 2Health News:Statement of Steve Pasierb, President and CEO, Partnership for a Drug-Free America on the Release of the 2007 Monitoring the Future Study 2Health News:Statement of Steve Pasierb, President and CEO, Partnership for a Drug-Free America on the Release of the 2007 Monitoring the Future Study 3Health News:Statement of Steve Pasierb, President and CEO, Partnership for a Drug-Free America on the Release of the 2007 Monitoring the Future Study 4
New!...
... I/A unit for planned ECCE with ... control). Independent irrigation, suction, reflux possible ... surgeon to control all critical functions. ... simultaneously. Preset and actual vacuum level ...
... Anterior and Posterior segment surgeries Vitrectomy-Lensectomy ... Ventury or Peristaltic Linear Aspiration. Interchangeable ... specific cutting action. Easy to read ... Cutting speed-variable from 1- 600 cuts ...
...
Medicine Products: